Wednesday, 11 August 2010 01:59 PM
Montreal, Wednesday, August 11, 2010 – Viropro announces a reshuffling of its management structure.
Viropro, Inc. announces it will be moving its head office from Montreal to California. California is generally regarded as the “Biotech Capital of the World.” This move is expected to place Viropro in a more favorable environment as regards exposure to financing activities in Biotechnology and as a launch pad for its global ambitions in biotech contract development and manufacturing operations. Viropro’s US subsidiary, Biologics Process Development (BPD), Inc. currently operates its lab facilities out of Poway/San Diego in California.
In keeping with this reorganization, Dr. Rajiv Datar is appointed President and Chief Executive Officer of the Company. Dr. Datar has been on the Board since August 2009 as representative of Intas Biopharmaceuticals Ltd.
Serge Beausoleil leaves the Board and becomes Advisor, Communications and Market Intelligence; Mr Beausoleil had been appointed President in January 2008. He had at that time orchestrated the Company’s turnaround, and at the end of the same year, secured an agreement with Intas that led to Intas becoming the controlling shareholder of Viropro, Inc. The Company would like to thank Mr Beausoleil for his excellent work during his tenure and has in fact asked him to stay and handle market related activities.
Jeff Hale, currently in charge of Business Development at Biologics Process Development, Inc., is appointed as the Chief Business Officer of Viropro, Inc. He will continue to manage the business development needs of BPD, Inc.
Finally, the Company announces the resignation of Claude Gingras as Vice-President, Corporate Affairs and Member of the Board. He will, however, remain as a Consulting CFO to the Company and will continue to assume corporate affairs.
About Viropro, Inc.:
Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)
About Biologics Process Development, Inc.:
Biologics Process Development, Inc. (BPD), located in Poway (San Diego area), California, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for fourteen years. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies. (www.biologicspd.com)
About Intas Biopharmaceuticals Limited:
Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility. (www.intasbiopharma.co.in)
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro:
For market related activities and investors information, please communicate with:
(514) 779-7336
For science related matters, please communicate with Rajiv Datar:
(949) 351-0860